PRPH ProPhase Labs Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRPH

Price (delayed)

$4.95

Market cap

$89.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.98

Enterprise value

$108.55M

ProPhase Labs is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, ...

Highlights
The net income has dropped by 191% year-on-year and by 60% since the previous quarter
The EPS has plunged by 184% YoY and by 56% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.prophaselabs.com
Peers: MTEX USNA NATR XOMA

Key stats

What are the main financial stats of PRPH
Market
Shares outstanding
18.05M
Market cap
$89.32M
Enterprise value
$108.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
1.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.45
Earnings
Revenue
$44.38M
EBIT
-$21.53M
EBITDA
-$14.83M
Free cash flow
-$14.46M
Per share
EPS
-$0.98
Free cash flow per share
-$0.84
Book value per share
$2.74
Revenue per share
$2.58
TBVPS
$4.32
Balance sheet
Total assets
$91.93M
Total liabilities
$42.54M
Debt
$21.38M
Equity
$49.38M
Working capital
$26.73M
Liquidity
Debt to equity
0.43
Current ratio
2.28
Quick ratio
1.99
Net debt/EBITDA
-1.3
Margins
EBITDA margin
-33.4%
Gross margin
36.6%
Net margin
-37.8%
Operating margin
-48.7%
Efficiency
Return on assets
-18.1%
Return on equity
-29.8%
Return on invested capital
-30.7%
Return on capital employed
-30.3%
Return on sales
-48.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRPH stock price

How has the ProPhase Labs stock price performed over time
Intraday
-2.17%
1 week
-9.01%
1 month
-20.16%
1 year
-35.96%
YTD
9.51%
QTD
-23.49%

Financial performance

How have ProPhase Labs's revenue and profit performed over time
Revenue
$44.38M
Gross profit
$16.24M
Operating income
-$21.61M
Net income
-$16.78M
Gross margin
36.6%
Net margin
-37.8%
The operating income has shrunk by 192% YoY and by 41% QoQ
The net income has dropped by 191% year-on-year and by 60% since the previous quarter
The net margin has plunged by 126% from the previous quarter
The company's operating margin has shrunk by 99% QoQ

Growth

What is ProPhase Labs's growth rate over time

Valuation

What is ProPhase Labs stock price valuation
P/E
N/A
P/B
1.81
P/S
1.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.45
The EPS has plunged by 184% YoY and by 56% from the previous quarter
PRPH's price to book (P/B) is 28% lower than its 5-year quarterly average of 2.5
ProPhase Labs's equity has decreased by 22% YoY and by 12% QoQ
PRPH's revenue has dropped by 64% year-on-year and by 29% since the previous quarter
The P/S is 28% higher than the last 4 quarters average of 1.5 but 13% lower than the 5-year quarterly average of 2.2

Efficiency

How efficient is ProPhase Labs business performance
ProPhase Labs's return on assets has shrunk by 194% YoY and by 57% QoQ
The return on invested capital has dropped by 171% year-on-year and by 31% since the previous quarter
The ROS has plunged by 97% from the previous quarter
PRPH's return on equity has dropped by 70% since the previous quarter

Dividends

What is PRPH's dividend history
Dividend details
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did ProPhase Labs financials performed over time
PRPH's total assets is 116% greater than its total liabilities
The company's total liabilities has surged by 77% YoY and by 21% QoQ
The company's quick ratio fell by 41% YoY and by 22% QoQ
The debt is 57% less than the equity
PRPH's debt to equity is up by 30% since the previous quarter
ProPhase Labs's equity has decreased by 22% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.